Here are three things to know:
1. Ortho RTi’s proprietary platform consists of the biopolymer chitosan, which is intended to be directly placed into the injury site during routine operative procedures.
2. The company develops treatments for rotator cuff and meniscus injuries.
3. The company issued a total of 450,000 Class “A” shares pursuant to the second tranche of its previously announced non-brokered private placement.
More articles on biologics:
23 developments in spine & orthopedic biologics research in 2018
3 things to know about AlloSource
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
